Membro del Comitato di Clinical Study Protocol Number / Version MV 17150D “A Randomized, Open-Label, Multicenter, efficacy and Safety Study Examining the Effect of Duration of Treatment and of a High Induction Dose of PEGASYS® in combination with Daiiy COPEGUS® IN Patients with Chronic Hepatitis C who Did Not Respond to Previous Peginterferon alfs-2b/Ribavirin Combination Therapy Acronym: REPEAT (RETREATMENT WITH PEgasys® in PATients Not Responding to Prior Peginterferon alfa-2b/Ribavirin Combination Therapy) Sponsor: Roche S.p.A / CRO: Quintiles S.p.A(2006).
Membro del Comitato di Clinical Study Protocol Number / Version MV 17150D “A Randomized, Open-Label, Multicenter, efficacy and Safety Study Examining the Effect of Duration of Treatment and of a High Induction Dose of PEGASYS® in combination with Daiiy COPEGUS® IN Patients with Chronic Hepatitis C who Did Not Respond to Previous Peginterferon alfs-2b/Ribavirin Combination Therapy Acronym: REPEAT (RETREATMENT WITH PEgasys® in PATients Not Responding to Prior Peginterferon alfa-2b/Ribavirin Combination Therapy) Sponsor: Roche S.p.A / CRO: Quintiles S.p.A.
2006
Pubblicazioni consigliate
I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR
